Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

#2152

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Aim(s): To assess response rates in NET G3 treated with different regimens.

Materials and methods: Retrospective analysis of patients(pts) treated 2006-2017. Radiological response and disease control rate (DCR) were assessed; progression-free survival(PFS) was determined by Kaplan-Meier and prognostic factors by Cox-regression model.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,